PCSK9
Evolocumab公司
阿利罗库单抗
可欣
以兹提米比
医学
前蛋白转化酶
内科学
药理学
内分泌学
胆固醇
低密度脂蛋白受体
脂蛋白
载脂蛋白A1
作者
Muharrem Akin,Thomas Skripuletz,L. Christian Napp,Dominik Berliner,Ibrahim Akin,Arash Haghikia,Elvan Akin,Johann Bauersachs
出处
期刊:Cardiovascular and Hematological Agents in Medicinal Chemistry
[Bentham Science]
日期:2017-01-18
卷期号:14 (2): 94-100
被引量:1
标识
DOI:10.2174/1871525714666160727113740
摘要
Statins are the most widely prescribed drugs to reduce serum low density lipoprotein cholesterol (LDL-C) by inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. LDL-C reduction is associated with a decreased risk of atherosclerotic cardiovascular disease (ASCVD), including cardiovascular disease (CVD) and stroke. Statins reduce LDL-C by 30 to 40%, and the combination with other lipid-lowering agents such as ezetimibe leads to a further reduction by 20 to 25%. However, even the combination of these two agents might not be sufficient in high risk patients to require aggressive LDL-C reduction. Therefore, starting from observations on individuals with loss-of-function in proprotein convertase subtilisin/kexin type 9 (PCSK9), which was associated with lower LDL-C levels and CVD rates, monoclonal antibodies (mAbs) against PCSK9 were developed. To date, two mAbs, alirocumab and evolocumab, have received approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the present review we give an overview about pathophysiological and clinical aspects as well as evidence for these drugs with respect to cerebrovascular events.
科研通智能强力驱动
Strongly Powered by AbleSci AI